VHL Gene Inactivation
2 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| A Phase 2 Study of Belzutifan (PT2977, MK-6482) for the Treatment of Von Hippel Lindau (VHL) Disease-Associated Renal Cell Carcinoma (RCC) (MK-6482-004) (NCT03401788) | Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2018-05-02 |
| MK-3795 (PT2385) for the Treatment of Von Hippel-Lindau Disease-Associated Clear Cell Renal Cell Carcinoma (MK-3795-003) (NCT03108066) | Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2017-04-24 |
Track VHL Gene Inactivation automatically
Every clearance here is in the API, with alerts when new ones post.